XBP1 and Miyoshi myopathy: Although the established mechanism of action of doxorubicin is through DNA/RNA intercalation and Topo II inhibition, this study indicates that it can also block XBP1 splicing as a separate mechanism for cytotoxicity in MM cells, suggesting additional clinical indications for this chemotherapeutic agent.